Sutro Biopharma (STRO) Net Cash Flow (2017 - 2025)

Sutro Biopharma has reported Net Cash Flow for 9 years, with the latest figure at -$7.8 million in Q4 2025.

• Quarterly Net Cash Flow fell 149.58% year-over-year to -$7.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$132.2 million (down 209.21% YoY) and the FY2025 annual result came in at -$132.2 million, down 209.21% from the prior year.
• Net Cash Flow fell to -$7.8 million in Q4 2025 per STRO's latest filing, from $1.9 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $172.6 million in Q2 2023 and troughed at -$153.3 million in Q3 2023.
• A 5-year average of -$7.4 million and a median of -$903000.0 in 2021 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2021 and 2022: Net Cash Flow sank 21127.27% in 2021, then surged 8648.08% in 2022.
• Over 5 years, Net Cash Flow stood at -$293000.0 in 2021, then slumped by 16802.73% to -$49.5 million in 2022, then soared by 74.63% to -$12.6 million in 2023, then surged by 225.15% to $15.7 million in 2024, then slumped by 149.58% to -$7.8 million in 2025.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$7.8 million, $1.9 million, and -$42.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.